Published • loading... • Updated
FTC requires divestitures for generic pharma deal
Summary by globalcompetitionreview.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
FTC requires divestitures for generic pharma deal
The Federal Trade Commission has approved Aurobindo Pharma’s $250 million acquisition of Lannett conditioned on the divestiture of four generic medications, marking the first instance the agency has imposed conditions on a pharmaceutical deal under the current administration.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
